Daniel El Fassi

Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation

Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment

Graves' Ophthalmopathy

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study

2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Attenuation of Induced Hyperthyroidism in Mice by Pretreatment with Thyrotropin Receptor Protein: Deviation of Thyroid-Stimulating to Nonfunctional Antibodies

A review of the current use of rituximab in autoimmune diseases

The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option

B-cell depletion with rituximab in the treatment of autoimmune diseases

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Evidence of Intrathyroidal B-Lymphocyte Depletion after rituximab Therapy in a Patient with Graves’ Disease

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot Study